文献速递消化、代谢与肾脏急症

阿柏西普与激光光凝或观察初始管理对糖尿病黄斑水肿累及黄斑中心且视力良好患者视力丧失的影响:一项随机临床试验

Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2019-01-01
一句话结论对于累及黄斑中心的糖尿病黄斑水肿且视力良好(20/25或更好)的眼,初始阿柏西普、激光光凝或观察并在视力恶化时给予阿柏西普,2年视力丧失无显著差异;作者认为观察直至视力恶化可能是合理策略。

该随机临床试验在美国和加拿大91个中心纳入702名1型或2型糖尿病成人,其一只研究眼有累及黄斑中心的糖尿病黄斑水肿且视力20/25或更好。研究眼随机分为玻璃体内注射阿柏西普2.0 mg(最多每4周一次,n=226)、局灶/格栅激光光凝(n=240)或观察(n=236);激光或观察组中若视力较基线下降至少10个字母(任意访视)或5至9个字母(连续2次访视),则需给予阿柏西普。2年时视力下降至少5个字母的比例在阿柏西普组为16%、激光组为17%、观察组为19%,两两比较风险差异和相对风险均无统计学显著差异(P=0.79)。抗血小板试验协作组血管事件在阿柏西普组15例(7%)、激光组13例(5%)、观察组8例(3%)。作者认为观察直至视力恶化可能是合理策略。

要点

  • 对于累及黄斑中心的糖尿病黄斑水肿且视力20/25或更好的眼,初始阿柏西普、激光光凝或观察(视力恶化时给予阿柏西普)2年视力下降至少5个字母的比例分别为16%、17%、19%,无显著差异(P=0.79)。
  • 阿柏西普组与激光组比较:风险差异-2%(95%CI -9%至5%),相对风险0.88(95%CI 0.57-1.35);阿柏西普组与观察组比较:风险差异-3%(95%CI -11%至4%),相对风险0.83(95%CI 0.55-1.27);激光组与观察组比较:风险差异-1%(95%CI -9%至6%),相对风险0.95(95%CI 0.64-1.41)。
  • 激光组25%(60/240)和观察组34%(80/236)的研究眼因视力较基线下降而启动阿柏西普。
  • 抗血小板试验协作组血管事件(心肌梗死、卒中或血管性/不明原因死亡)在阿柏西普组15例(7%)、激光组13例(5%)、观察组8例(3%)。
  • 作者认为,对于累及黄斑中心的糖尿病黄斑水肿且视力良好的眼,观察直至视力恶化可能是合理策略。

适用人群与场景

  • 美国和加拿大91个中心纳入的702名1型或2型糖尿病成人,研究眼有累及黄斑中心的糖尿病黄斑水肿且视力20/25或更好。

诊断标准与关键阈值

  • 累及黄斑中心的糖尿病黄斑水肿(CI-DME)且研究眼视力20/25或更好。
  • 激光光凝或观察组中,若视力较基线下降至少10个字母(任意访视)或下降5至9个字母(连续2次访视),则需给予阿柏西普。

处置流程与药物剂量

  • 研究眼随机分配至玻璃体内注射阿柏西普2.0 mg(最多每4周一次,n=226)、局灶/格栅激光光凝(n=240)或观察(n=236)。
  • 激光光凝或观察组的研究眼,若视力较基线下降至少10个字母(任意访视)或下降5至9个字母(连续2次访视),则给予阿柏西普。

研究设计与关键结果

  • 随机临床试验,91个美国及加拿大中心,702名1型或2型糖尿病成人,研究眼有累及黄斑中心的糖尿病黄斑水肿且视力20/25或更好;随机分为阿柏西普2.0 mg玻璃体内注射(n=226)、局灶/格栅激光光凝(n=240)或观察(n=236)。
  • 2年时视力下降至少5个字母的比例:阿柏西普组16%(33/205)、激光组17%(36/212)、观察组19%(39/208);阿柏西普 vs 激光:风险差异-2%(95%CI -9%至5%),相对风险0.88(95%CI 0.57-1.35),P=0.79;阿柏西普 vs 观察:风险差异-3%(95%CI -11%至4%),相对风险0.83(95%CI 0.55-1.27),P=0.79;激光 vs 观察:风险差异-1%(95%CI -9%至6%),相对风险0.95(95%CI 0.64-1.41),P=0.79。
  • 激光组25%(60/240)和观察组34%(80/236)的研究眼因视力较基线下降而启动阿柏西普。
  • 抗血小板试验协作组血管事件:阿柏西普组15例(7%)、激光组13例(5%)、观察组8例(3%)。

证据类型、等级与局限

  • 证据类型:随机临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于累及黄斑中心的糖尿病黄斑水肿且视力良好(20/25或更好)的眼,初始阿柏西普、激光光凝或观察(视力恶化时给予阿柏西普)2年视力丧失无显著差异;作者认为观察直至视力恶化可能是合理策略。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Intravitreous injections of antivascular endothelial growth factor agents are effective for treating diabetic macular edema (DME) involving the center of the macula (center-involved DME [CI-DME]) with visual acuity impairment (20/32 or worse). The best approach to treating patients with CI-DME and good visual acuity (20/25 or better) is unknown.

OBJECTIVE: To compare vision loss at 2 years among eyes initially managed with aflibercept, laser photocoagulation, or observation.

DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial conducted at 91 US and Canadian sites among 702 adults with type 1 or type 2 diabetes. Participants had 1 study eye with CI-DME and visual acuity of 20/25 or better. The first participant was randomized on November 8, 2013, and the final date of follow-up was September 11, 2018.

INTERVENTIONS: Eyes were randomly assigned to 2.0 mg of intravitreous aflibercept (n = 226) as frequently as every 4 weeks, focal/grid laser photocoagulation (n = 240), or observation (n = 236). Aflibercept was required for eyes in the laser photocoagulation or observation groups that had decreased visual acuity from baseline by at least 10 letters (≥ 2 lines on an eye chart) at any visit or by 5 to 9 letters (1-2 lines) at 2 consecutive visits.

MAIN OUTCOMES AND MEASURES: The primary outcome was at least a 5-letter visual acuity decrease from baseline at 2 years. Antiplatelet Trialists' Collaboration adverse events (defined as myocardial infarction, stroke, or vascular or unknown death) were reported.

RESULTS: Among 702 randomized participants (mean age, 59 years; 38% female [n=264]), 625 of 681 (92% excluding deaths) completed the 2-year visit. For eyes with visual acuity that decreased from baseline, aflibercept was initiated in 25% (60/240) and 34% (80/236) in the laser photocoagulation and observation groups, respectively. At 2 years, the percentage of eyes with at least a 5-letter visual acuity decrease was 16% (33/205), 17% (36/212), and 19% (39/208) in the aflibercept, laser photocoagulation, and observation groups, respectively (aflibercept vs laser photocoagulation risk difference, -2% [95% CI, -9% to 5%]; relative risk, 0.88 [95% CI, 0.57-1.35; P = .79]; aflibercept vs observation risk difference, -3% [95% CI, -11% to 4%]; relative risk, 0.83 [95% CI, 0.55-1.27; P = .79]; laser photocoagulation vs observation risk difference, -1% [95% CI, -9% to 6%]; relative risk, 0.95 [95% CI, 0.64-1.41; P = .79]). Antiplatelet Trialists' Collaboration vascular events occurred in 15 (7%), 13 (5%), and 8 (3%) participants in the aflibercept, laser photocoagulation, and observation groups.

CONCLUSIONS AND RELEVANCE: Among eyes with CI-DME and good visual acuity, there was no significant difference in vision loss at 2 years whether eyes were initially managed with aflibercept or with laser photocoagulation or observation and given aflibercept only if visual acuity worsened. Observation without treatment unless visual acuity worsens may be a reasonable strategy for CI-DME.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01909791.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Baker CW, Glassman AR, Beaulieu WT, et al. Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial. JAMA. 2019. PMID: 31037289. doi:10.1001/jama.2019.5790

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。